Esketamine for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 10 registered trials.

Why this status

  1. 15 Apr 2015: Trial registered, NCT02417064
  2. 16 Apr 2015: Trial registered, NCT02418585
  3. 21 Apr 2015: Trial registered, NCT02422186
  4. 7 Aug 2015: Trial started, NCT02418585
  5. 10 Aug 2015: Trial started, NCT02417064
  6. 20 Aug 2015: Trial started, NCT02422186
  7. 25 May 2016: Trial registered, NCT02782104
  8. 9 Jun 2016: Trial started, NCT02782104
  9. 15 Feb 2018: Trial registered, NCT03434041
  10. 25 May 2018: Trial started, NCT03434041
  11. 23 Oct 2020: Trial registered, NCT04599855
  12. 4 Nov 2020: Trial started, NCT04599855
  13. 9 Jun 2025: Trial started, NCT07053345
  14. 8 Jul 2025: Trial registered, NCT07053345

The trials

NCT01640080: A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

State
Completed
Phase
Phase 2
People
30 taking part
Started
27 Jun 2012
Primary completion
3 Jun 2013
Arms
Esketamine (Group 1), Esketamine (Group 2)
Results
None posted
  1. 27 Jun 2012: Trial started
  2. 13 Jul 2012: Trial registered
  3. 3 Jun 2013: Trial completed

NCT02417064: A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
346 taking part
Started
10 Aug 2015
Primary completion
20 Feb 2018
Arms
Intranasal Esketamine 84mg plus Oral Antidepressant, Esketamine 56 mg plus Oral Antidepressant
Results
Posted on the registry
  1. 15 Apr 2015: Trial registered
  2. 10 Aug 2015: Trial started
  3. 20 Feb 2018: Trial completed
  4. 18 Apr 2019: Trial results posted

NCT02418585: A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
236 taking part
Started
7 Aug 2015
Primary completion
1 Jun 2017
Arms
Intranasal Esketamine plus oral antidepressant
Results
Posted on the registry
  1. 16 Apr 2015: Trial registered
  2. 7 Aug 2015: Trial started
  3. 6 Nov 2017: Trial completed
  4. 19 Apr 2019: Trial results posted

NCT02422186: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
139 taking part
Started
20 Aug 2015
Primary completion
10 Aug 2017
Arms
Intranasal Esketamine plus Oral Antidepressant
Results
Posted on the registry
  1. 21 Apr 2015: Trial registered
  2. 20 Aug 2015: Trial started
  3. 10 Aug 2017: Trial completed
  4. 24 Apr 2019: Trial results posted

NCT02782104: A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
1,148 taking part
Started
9 Jun 2016
Primary completion
30 Dec 2022
Arms
Esketamine Nasal Spray
Results
Posted on the registry
  1. 25 May 2016: Trial registered
  2. 9 Jun 2016: Trial started
  3. 30 Dec 2022: Trial completed
  4. 20 Feb 2024: Trial results posted

NCT03434041: A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
252 taking part
Started
25 May 2018
Primary completion
13 Apr 2021
Arms
Intranasal Esketamine plus Oral Antidepressant
Results
Posted on the registry
  1. 15 Feb 2018: Trial registered
  2. 25 May 2018: Trial started
  3. 13 Apr 2021: Trial completed
  4. 24 May 2022: Trial results posted

NCT03852160: A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
1 Dec 2019
Primary completion
25 Jul 2021
Arms
Esketamine + Oral Antidepressants
Results
None posted
  1. 25 Feb 2019: Trial registered
  2. 27 Apr 2025: Trial withdrawn

NCT04599855: A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 4
People
477 taking part
Started
4 Nov 2020
Primary completion
31 Jan 2024
Arms
Esketamine 56 Milligram (mg), Esketamine 84 mg
Results
Posted on the registry
  1. 23 Oct 2020: Trial registered
  2. 4 Nov 2020: Trial started
  3. 31 Jan 2024: Trial completed
  4. 4 Mar 2025: Trial results posted

NCT04924257: ECT vs. Esketamine

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
28 Jul 2021
Primary completion
Aug 2023
Arms
Intranasal Esketamine
Results
None posted
  1. 11 Jun 2021: Trial registered
  2. 28 Jul 2021: Trial started
  3. 5 Aug 2022: Trial withdrawn

NCT07053345: A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 4
People
47 taking part
Started
9 Jun 2025
Primary completion
13 Jul 2026
Arms
Esketamine Nasal Spray
Results
None posted
  1. 9 Jun 2025: Trial started
  2. 8 Jul 2025: Trial registered
  3. 13 Jul 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Esketamine (Intranasal Spray), Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Esketamine DPI - high dose, Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine Nasal Product, Esketamine Nasal Spray, Intranasal esketamine (28 mg), Intranasal esketamine (56 mg), Intranasal esketamine (84 mg), Keta-s, Ketaved.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.